5-Amino-1MQ

Read 1. No age-qualified male 45–60 self-reports were identifiable in the readable threads, and none of the counted reporters explicitly self-identified as male, so both male blocks remain empty. Across five distinct first-person reporters, experiences ranged from energy/clarity and modest fat-loss observations to no meaningful fat-loss effect; one reporter stopped after a reproducible adverse reaction that they suspected reflected a mislabeled or poor-quality product. The clearest adverse reports were gut cramping, a fluttery/amped feeling, and the unusual urinary/pelvic symptoms in the product-quality case. Onset for subjective energy could be immediate, whereas body-composition effects, where claimed, were slower; stacking with Reta/NAD or other compounds made attribution difficult. The sample is far below the requested target because several seed threads were question-only, inaccessible, or contained no qualifying first-person report.

Read 2. No man aged 45–60 (an "old" r/BodyHackGuide commenter was excluded). Of 22 self-reporters across 20 threads, 10 positive, 3 mixed, 3 negative, 6 unclear; fat loss (especially midsection) and clean energy led the benefits. Side effects were GI upset including severe gastritis, fatigue, and one case of severe low blood sugar (52 mg/dL) when stacked with tirzepatide. Cycles ran 2–6 weeks; users are confused between microgram SubQ and milligram oral/injectable dosing.

Note 1. Very small sample. Product identity and quality were explicit concerns in one adverse report. Several users stacked 5-Amino-1MQ, making causal attribution weak.

Note 2. Six r/BodyHackGuide threads were excluded. Dosing reports split between mcg-level SubQ vials and 50-150 mg oral/injectable protocols.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.